ARQT logoARQT
Arcutis Biotherapeutics Inc

2,437
Loading...
Loading...
News
all
press releases
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 45.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·8d ago
News Placeholder
More News
News Placeholder
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Foghorn Therapeutics Inc. (FHTX) have performed compared to their sector so far this year.
Zacks·13d ago
News Placeholder
Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·26d ago
News Placeholder
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Tenet Healthcare (THC) have performed compared to their sector so far this year.
Zacks·29d ago
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates
chainwire·4mo ago
News Placeholder
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally
Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.
Stocktwits·7mo ago
News Placeholder
Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"
Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a 'Clear Win for Your Skin' Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a 'Clear Win for Your Skin' PR Newswire...
PR Newswire·7mo ago
News Placeholder
Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts
Latest Ratings for ARQT DateFirmActionFromTo Mar 2022Morgan StanleyMaintainsOverweight Nov 2021Morgan StanleyMaintainsOverweight Jul 2021Morgan StanleyMaintainsOverweight View More Analyst...
Benzinga·1y ago

Latest ARQT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.